# US 2024/0401076 A1 · Self-replicating rna molecules and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0401076 A1
- Document ID: US20240401076A1
- Status: Published application
- Kind: A1
- Application number: 18/630,513
- Filed: 2024-04-09
- Published: 2024-12-05
- Earliest claimed: 2021-10-09
- Applicants: R&R Therapeutics Inc.
- Inventors: Kexing WU
- Web page: https://patentgrep.com/patent/US20240401076A1

## CPC

- C12N 15/86: Viral vectors
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 39/00: General protective or antinoxious agents
- C07K 14/005: from viruses
- C07K 14/145: Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
- C12N 15/64: General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- C12N 2760/20122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20242: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2760/20243: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided are a self-replicating RNA molecule and uses thereof. The self-replicating RNA molecule includes: a first RNA sequence encoding an N protein or a functional fragment of the N protein, a second RNA sequence encoding a P protein or a functional fragment of the P protein, and a third RNA sequence encoding an L protein or a functional fragment of the L protein. The self-replicating RNA molecule is suitable for producing the N protein, the P protein, the L protein, or the functional fragments thereof in animal cells.

## Claims

### Claim 1

A self-replicating RNA molecule, comprising:
a first RNA sequence, encoding an N protein or a functional fragment of the N protein,
a second RNA sequence, encoding a P protein or a functional fragment of the P protein, and
a third RNA sequence, encoding an L protein or a functional fragment of the L protein,
wherein the self-replicating RNA molecule is suitable for producing the N protein, the P protein, the L protein, or the functional fragments thereof in animal cells.

### Claim 2 (depends on 1)

The self-replicating RNA molecule according to claim 1, wherein at least one of the N protein, the P protein, and the L protein is independently derived from Rhabdoviridae virus.

### Claim 3 (depends on 2)

The self-replicating RNA molecule according to claim 2, wherein the Rhabdoviridae virus comprises at least one virus selected from Vesiculorius, Lyssavirus, and Ephemerovirus.

### Claim 4 (depends on 2)

The self-replicating RNA molecule according to claim 2, wherein the Rhabdoviridae virus comprises at least one virus selected from Vesicular stomatitis New Jersey virus, Maraba virus, Vesicular stomatitis Alagoas virus Indiana 3, Cocal virus Indiana 2, Isfahan virus, Chandipura virus, Spring viraemia of carp virus, American bat vesiculovirus, Carajas vesiculovirus, Jurona vesiculovirus, Malpais Spring vesiculovirus, Morreton vesiculovirus, Perinet vesiculovirus, Piry vesiculovirus, Radi vesiculovirus, Yug Bogdanovac vesiculovirus, West Caucasian bat virus. Aravan lyssavirus, Khujand lyssavirus, Rabies virus, Australian bat lyssavirus, European bat lyssavirus 1, European bat lyssavirus 2, Irkut virus, Shimoni bat virus, Lagos bat virus, Mokola virus, Lleida bat lyssavirus, Ikoma lyssavirus, Gannoruwa bat lyssavirus, Bokeloh bat lyssavirus, Duvenhage lyssavirus, Bovine fever ephemerovirus, Adelaide River ephemerovirus, Berrimah ephemerovirus, and Kimberley ephemerovirus.

### Claim 5 (depends on 1)

The self-replicating RNA molecule according to claim 1, wherein:
the N protein has an amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 19, or SEQ ID NO: 25, or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity with the amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 19, or SEQ ID NO: 25;
the P protein has an amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 14, SEQ ID NO: 20, or SEQ ID NO: 26, or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity with the amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 14, SEQ ID NO: 20, or SEQ ID NO: 26; and
the L protein has an amino acid sequence as set forth in SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 15, SEQ ID NO: 21, or SEQ ID NO: 27, or an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity with the amino acid sequence as set forth in SEQ ID NO: 3, SEQ ID NO: 9, SEQ ID NO: 15, SEQ ID NO: 21, or SEQ ID NO: 27.

### Claim 6 (depends on 5)

The self-replicating RNA molecule according to claim 5, wherein:
the N protein has the amino acid sequence as set forth in SEQ ID NO: 1, the P protein has the amino acid sequence as set forth in SEQ ID NO: 2, and the L protein has the amino acid sequence as set forth in SEQ ID NO: 3; or
the N protein has the amino acid sequence as set forth in SEQ ID NO: 7, the P protein has the amino acid sequence as set forth in SEQ ID NO: 8, and the L protein has the amino acid sequence as set forth in SEQ ID NO: 9; or
the N protein has the amino acid sequence as set forth in SEQ ID NO: 13, the P protein has the amino acid sequence as set forth in SEQ ID NO: 14, and the L protein has the amino acid sequence as set forth in SEQ ID NO: 15; or
the N protein has the amino acid sequence as set forth in SEQ ID NO: 19, the P protein has the amino acid sequence as set forth in SEQ ID NO: 20, and the L protein has the amino acid sequence as set forth in SEQ ID NO: 21; or
the N protein has the amino acid sequence as set forth in SEQ ID NO: 25, the P protein has the amino acid sequence as set forth in SEQ ID NO: 26, and the L protein has the amino acid sequence as set forth in SEQ ID NO: 27.

### Claim 7 (depends on 1)

The self-replicating RNA molecule according to claim 1, wherein:
the first RNA sequence has a base sequence as set forth in SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 16, SEQ ID NO: 22, or SEQ ID NO: 28, or has a base sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity with the base sequence as set forth in SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 16, SEQ ID NO: 22, or SEQ ID NO: 28;
the second RNA sequence has a base sequence as set forth in SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 17, SEQ ID NO: 23, or SEQ ID NO: 29, or has a base sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity with the base sequence as set forth in SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 17, SEQ ID NO: 23, or SEQ ID NO: 29; and
the third RNA sequence has a base sequence as set forth in SEQ ID NO: 6, SEQ ID NO: 12, SEQ ID NO: 18, SEQ ID NO: 24, or SEQ ID NO: 30, or has a base sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity with the base sequence as set forth in SEQ ID NO: 6, SEQ ID NO: 12, SEQ ID NO: 18, SEQ ID NO: 24, or SEQ ID NO: 30.

### Claim 8 (depends on 7)

The self-replicating RNA molecule according to claim 7, wherein:
the first RNA sequence has the base sequence as set forth in SEQ ID NO: 4, the second RNA sequence has the base sequence as set forth in SEQ ID NO: 5, and the third RNA sequence has the base sequence as set forth in SEQ ID NO: 6; or
the first RNA sequence has the base sequence as set forth in SEQ ID NO: 10, the second RNA sequence has the base sequence as set forth in SEQ ID NO: 11, and the third RNA sequence has the base sequence as set forth in SEQ ID NO: 12; or
the first RNA sequence has the base sequence as set forth in SEQ ID NO: 16, the second RNA sequence has the base sequence as set forth in SEQ ID NO: 17, and the third RNA sequence has the base sequence as set forth in SEQ ID NO: 18; or
the first RNA sequence has the base sequence as set forth in SEQ ID NO: 22, the second RNA sequence has the base sequence as set forth in SEQ ID NO: 23, and the third RNA sequence has the base sequence as set forth in SEQ ID NO: 24; or
the first RNA sequence has the base sequence as set forth in SEQ ID NO: 28, the second RNA sequence has the base sequence as set forth in SEQ ID NO: 29, and the third RNA sequence has the base sequence as set forth in SEQ ID NO: 30.

### Claim 9 (depends on 1)

The self-replicating RNA molecule according to claim 1, further comprising:
a target molecule coding region, encoding at least one target molecule.

### Claim 10 (depends on 9)

The self-replicating RNA molecule according to claim 9, wherein the target molecule is suitable to serve as at least one of nucleic acid medicaments, protein medicaments, pathogen vaccines, tumor vaccines, and therapeutic agents for rare diseases.

### Claim 11 (depends on 9)

The self-replicating RNA molecule according to claim 9, wherein:
the target molecule coding region encodes at least one of fluorescent protein, granulocyte-macrophage colony stimulating factor, and OVA; and
optionally, the fluorescent protein comprises at least one of green fluorescent protein, red fluorescent protein, and yellow fluorescent protein.

### Claim 12 (depends on 1)

A DNA molecule, encoding the self-replicating RNA molecule according to claim 1.

### Claim 13 (depends on 12)

An expression vector, carrying the DNA molecule according to claim 12.

### Claim 14 (depends on 1)

A method for preparing the self-replicating RNA molecule according to claim 1, the method comprising:
expressing, using a DNA molecule encoding the self-replicating RNA molecule or an expression vector carrying a DNA molecule encoding the self-replicating RNA molecule, the self-replicating RNA molecule in host cells; and
collecting the self-replicating RNA molecule.

### Claim 15 (depends on 1)

An RNA-protein complex, comprising:
the self-replicating RNA molecule according to claim 1; and
a protein, comprising the N protein or functional fragment thereof, the P protein or functional fragment thereof, and the L protein or functional fragment thereof.

### Claim 16 (depends on 1)

A pharmaceutical composition, comprising
the self-replicating RNA molecule according to claim 1; or
an DNA molecule encoding the self-replicating RNA molecule; or
an expression vector carrying an DNA molecule encoding the self-replicating RNA molecule; or
an RNA-protein complex, comprising the self-replicating RNA molecule and a protein, wherein the protein comprises the N protein or functional fragment thereof, the P protein or functional fragment thereof, and the L protein or functional fragment thereof.

### Claim 17 (depends on 1)

A method for expressing a target molecule in an individual, the method comprising:
administering to the individual the self-replicating RNA molecule according to claim 1.
